Clinical Trials for Ovarian Cancer

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and previously treated, refractory, locally advanced unresectable or metastatic solid tumors across multiple tumor-specific cohorts receive patritumab deruxtecan 5.6 mg/kg IV every 3 weeks. This investigational HER3-targeted antibody–drug conjugate delivers an exatecan-derived topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT06172478

RESOLVE: letRozole abEmaciclib combinationS in endOmetriaL and oVarian cancEr: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination With Metformin, Zotatifin and Gedatolisib

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent, metastatic, or treatment-resistant endometrial cancer (generally ER-positive) or low-grade serous ovarian, fallopian tube, or peritoneal carcinoma receive letrozole (aromatase inhibitor) plus abemaciclib (CDK4/6 inhibitor), or abemaciclib without letrozole in one cohort. Depending on cohort, treatment adds metformin, zotatifin (eIF4A translation inhibitor), gedatolisib (PI3K/mTOR inhibitor), or samotolisib (PI3K/mTOR/DNA-PK inhibitor); one cohort requires progression after prior CDK4/6 inhibition.

ClinicalTrials.gov ID: NCT03675893

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously treated, measurable recurrent or progressive gynecologic cancer and a RAS/BRAF pathway alteration receive avutometinib, a dual RAF/MEK inhibitor, plus defactinib, a focal adhesion kinase inhibitor. Low-grade serous ovarian cancer and prior RAF or MEK inhibitor exposure are excluded.

ClinicalTrials.gov ID: NCT05512208

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Patients aged ≥10 years with advanced solid tumors or recurrent or progressive primary CNS tumors harboring eligible BRAF fusions or BRAF V600E mutations receive plixorafenib, an oral inhibitor of BRAF V600 signaling and BRAF-containing dimers. Depending on the tumor cohort, plixorafenib is given alone or with cobicistat to increase plixorafenib exposure; patients with metastatic cutaneous melanoma or thyroid cancer are randomized between these regimens.

ClinicalTrials.gov ID: NCT05503797

A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls women with measurable platinum-resistant or refractory high-grade serous ovarian, fallopian tube, or primary peritoneal cancer, ECOG 0–1, and no more than two additional systemic regimens for advanced disease. Patients are randomized to IV CBX-12 at 125 or 100 mg/m² every 21 days; CBX-12 is a pH-sensitive peptide–drug conjugate carrying the topoisomerase I inhibitor exatecan.

ClinicalTrials.gov ID: NCT06315491

Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For patients with measurable, progressive platinum-resistant serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer and ECOG performance status 0–1, this study evaluates ubamatamab, an investigational MUC16×CD3 T-cell–engaging bispecific antibody, with sarilumab. Other arms add bevacizumab, pegylated liposomal doxorubicin, or cemiplimab plus investigational fianlimab, an anti–LAG-3 antibody.

ClinicalTrials.gov ID: NCT06787612

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with measurable, platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer are treated with oral azenosertib, an investigational WEE1 kinase inhibitor that disrupts the DNA-damage checkpoint. The enrolling portion requires cyclin E1-positive tumors and compares two azenosertib doses without a standard-treatment control arm.

ClinicalTrials.gov ID: NCT05128825

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable recurrent serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer, ECOG 0–1, and no more than three prior treatment lines are eligible, whether platinum-sensitive or platinum-resistant; patients who progressed on prior immune checkpoint blockade are excluded. Participants receive pembrolizumab (PD-1 inhibitor) and bevacizumab (VEGF inhibitor), with or without investigational CDX-1140, a CD40 agonist antibody intended to stimulate immune activation.

ClinicalTrials.gov ID: NCT05231122

Phase 2, Randomized, Prospective, Open-Label, Parallel-Arm, Dose Optimization Study to Investigate the Safety, Tolerability, PK/PD, and Anti- Tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with measurable, recurrent high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer that is platinum resistant or platinum ineligible receive one of two oral doses of stenoparib, without a standard-treatment control. Stenoparib inhibits PARP1/2-mediated DNA repair and tankyrase 1/2, which regulate Wnt/β-catenin signaling.

ClinicalTrials.gov ID: NCT03878849

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Women with unresectable, platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer after at least three prior systemic therapies, including bevacizumab, are randomized to intraperitoneal Olvi-Vec followed by a platinum doublet and bevacizumab or physician-selected chemotherapy plus bevacizumab. Olvi-Vec is an investigational oncolytic vaccinia virus designed to lyse tumor cells and stimulate antitumor immunity.

ClinicalTrials.gov ID: NCT05281471